EP Winer

1.8k citations
40 papers · 530 · h-index 10

Impact in

  • Oncology top 10%
    • HER2/EGFR in Cancer Research
    • Cancer survivorship and care
    • Cancer Treatment and Pharmacology
    • Cancer Risks and Factors
    • Cancer Immunotherapy and Biomarkers
  • Cancer Research top 10%
    • Breast Cancer Treatment Studies

Papers in

  • Oncology 32
    • Cancer Treatment and Pharmacology 13
    • HER2/EGFR in Cancer Research 8
    • Cancer Immunotherapy and Biomarkers 4
    • Cancer survivorship and care 4
    • Cancer Risks and Factors 4
  • Pulmonary and Respiratory Medicine 23
    • Advanced Breast Cancer Therapies 19
Co-authors
Kathleen A. Havlin (1 shared paper)Vera Hárs (1 shared paper)Wendy Demark‐Wahnefried (1 shared paper)AH Partridge (4 shared papers)Shari Gelber (2 shared papers)R. Rosenberg (1 shared paper)Clifford A. Hudis (3 shared papers)C. Cirrincione (2 shared papers)
Journals
Cancer Research (32 papers)Annals of Oncology (5 papers)Journal of Clinical Oncology (2 papers)American Journal of Clinical Nutrition (1 paper)
Partner nations
United StatesJapanAustralia

In The Last Decade

EP Winer

39 papers receiving 510 citations

Peers

EP Winer
Comparison fields: 5 of 59
  • Oncology 443
  • Cancer Research 208
  • Pulmonary and Respiratory Medicine 115
  • Physiology 91
  • Pediatrics, Perinatology and Child Health 46
Replace Sebastian Lundgren with:
Sebastian Lundgren Sweden
C. Seynaeve Netherlands
Lorenzo Rossi Switzerland
Friedrich Overkamp Germany
Valeria Forestieri Italy
Domen Ribnikar Slovenia
Sara Taylor Canada
Anne S. Quante Germany
C. I. Li United States
Lore Lapeire Belgium
EP Winer relative to Sebastian Lundgren Sweden Sebastian Lundgren's profile →
Citations per field
00.5×2×3×4×
Sebastian Lundgren · 1×
Citations per year

Countries citing papers authored by EP Winer

Since Specialization
Citations

This map shows the geographic impact of EP Winer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EP Winer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EP Winer more than expected).

Fields of papers citing papers by EP Winer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EP Winer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EP Winer. The network helps show where EP Winer may publish in the future.

Co-authors

The 25 scholars most cited alongside EP Winer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with EP Winer Line = papers co-authored together EP Winer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy
American Journal of Clinical Nutrition ·Wendy Demark‐Wahnefried, Vera Hárs, MR Conaway, Kathleen A. Havlin, Rimer Bk, Gregory McElveen, EP Winer
1997160
2
Menopausal-type symptoms in young breast cancer survivors
Annals of Oncology ·M.G. Leining, Shari Gelber, R. Rosenberg, M. Przypyszny, EP Winer, AH Partridge
200672
3
Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)
Cancer Research ·W. M. Sikov, DA Berry, CM Perou, Bhupender Singh, C. Cirrincione, SM Tolaney, George Somlo, ER Port, R Qamar, Keren Sturtz, Eleftherios P. Mamounas, Mehra Golshan, J.R. Bellon, Deborah Collyar, O Hahn, LA Carey, CA Hudis, EP Winer
201651
4
CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
Journal of Clinical Oncology ·Andrew D. Seidman, D. A. Berry, C. Cirrincione, L. Harris, L. G. Dressler, Hyman B. Muss, Larry Norton, EP Winer, Clifford A. Hudis
200449
5
Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
Cancer Research ·W. M. Sikov, DA Berry, CM Perou, Bhupender Singh, Constance Cirrincione, Sara M. Tolaney, C. Kuzma, TJ Pluard, George Somlo, Elisa Port, Mehra Golshan, J.R. Bellon, Deborah Collyar, O Hahn, LA Carey, Clifford A. Hudis, EP Winer
201339
6
296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
Annals of Oncology ·Leisha A. Emens, Luciana Molinero, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiß, Véronique Dièras, Hiroji Iwata, Carlos H. Barrios, M. Nechaeva, EP Winer, CL Chang, Jane Yuet Ching Hui, Peter Schmid, Sherene Loi
202023
7
Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
Cancer Research ·Sylvia Adams, Sherene Loi, D. Toppmeyer, DW Cescon, Michelino De Laurentiis, Rita Nanda, EP Winer, Hirofumi Mukai, Kenji Tamura, AC Armstrong, MC Liu, Hiroji Iwata, L Ryvo, Pauline Wimberger, HS Rugo, Antoinette R. Tan, C D'Aquanno, Yi Ding, Vassiliki Karantza, Peter Schmid
201822
8
Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
Cancer Research ·SM Tolaney, WT Barry, CT Dang, DA Yardley, Beverly Moy, P. Kelly Marcom, KS Albain, HS Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, LA Carey, BA Overmoyer, AH Partridge, Hao Guo, CA Hudis, IE Krop, HJ Burstein, EP Winer
201322
9
P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy.
Cancer Research ·LC Collins, Shari Gelber, JD Marotti, K. L. Cole, Sandra Kereakoglow, KJ Ruddy, EF Brachtel, Lidia Schapira, SE Come, VF Borges, PJ Schedin, Erica T. Warner, EP Winer, Ann H. Partridge
201112
10
Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer
Cancer Research ·Rinath Jeselsohn, Hao Guo, Rebecca Rees, WT Barry, CH Barlett, NM Tung, IE Krop, Myles Brown, EP Winer
20199
11
49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Annals of Oncology ·Hitoshi Iwata, Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Sherene Loi, H. S. Rugo, Andreas Schneeweiß, EP Winer, S. Patel, Volkmar Henschel, A. Swat, M. Kaul, L. Molinero, S.S. Chui, Patrick Schmid
20208
12
Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer
Cancer Research ·IE Krop, Antonio C. Wolff, EP Winer, KD Miller, BH Park, J. A. Ware, S. Holden, G. G. Levy, Mika K. Derynck, AM Storniolo
20108
13
Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer
Cancer Research ·EL Mayer, SA Wander, MM Regan, A. DeMichele, Andres Forero, MF Rimawi, CX Ma, M Cristofanilli, CK Anders, C Huang Bartlett, María Koehler, EP Winer, HJ Burstein
20188
14
Abstract GS5-05: Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance)
Cancer Research ·ES Hwang, Stephanie Q. Duong, I. Bedrosian, Jacob B. Allred, Dorota J. Wisner, Terry Hyslop, Abigail S. Caudle, J. Michael Guenther, C. Hudis, EP Winer, L. Esserman, Nola Hylton
20185
15
Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer.
Cancer Research ·SJ Isakoff, PE Goss, EL Mayer, Tiffany A. Traina, LA Carey, KJ Krag, MC Liu, Hope S. Rugo, Vered Stearns, Steven E. Come, Dianne M. Finkelstein, A-R Hartman, J. E. Garber, Patrick J. Ryan, EP Winer, LW Ellisen
20125
16
Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab
Cancer Research ·IE Krop, DW Hillman, M-Y Polley, Maki Tanioka, Joseph F. Parker, L Huebner, N. Lynn Henry, SM Tolaney, Celeste Dang, Lyndsay Harris, DA Berry, CM Perou, Ann H. Partridge, EP Winer, LA Carey
20184
17
42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
Annals of Oncology ·Otto Metzger, Chiara Lambertini, IE Krop, Gail D. Lewis Phillips, Charles M. Perou, F. Symmans, Ignacio Melero, Nadia Harbeck, EP Winer, S-A. Im, Carlos H. Barrios, Hervé Bonnefoi, Julie R. Gralow, Peter Ellis, Lorenzo Gianni, Masakazu Toi, Sandra M. Swain, Thomas Boulet, Chunyan Song, SL de Haas
20213
18
Abstract S5-05: Impact of pre-operative exercise on breast cancer gene expression
Cancer Research ·JA Ligibel, Melinda L. Irwin, Deborah Dillon, W Barry, Anita Giobbie‐Hurder, Elizabeth S. Frank, EP Winer, Anne McTiernan, MacIntosh Cornwell, Matthew Pun, Myles Brown, Rinath Jeselsohn
20173
19
Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases
Cancer Research ·RA Freedman, RS Gelman, J.S. Wefel, IE Krop, ME Melisko, Amy Ly, NYR Agar, RM Connolly, KL Blackwell, LM Nabell, JN Ingle, CH Van Poznak, SL Puhalla, PA Niravath, Nicole Ryabin, Antonio C. Wolff, EP Winer, Nancy U. Lin
20123
20
Abstract S2-6: Aromatase Inhibitors and Risk of Myocardial Infarction, Stroke and Fracture
Cancer Research ·JA Ligibel, A J O’Malley, Mary Insana Fisher, GW Daniel, EP Winer, NL Keating
20102

About EP Winer

EP Winer is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 40 papers that have together received 530 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (8 papers), Cancer Genomics and Diagnostics (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer survivorship and care (4 papers) and Cancer Risks and Factors (4 papers). The work is most often cited by research in Oncology (443 citations), Cancer Research (208 citations), Pulmonary and Respiratory Medicine (115 citations), Physiology (91 citations) and Pediatrics, Perinatology and Child Health (46 citations). EP Winer has collaborated with scholars based in United States, Japan and Australia. Frequent co-authors include Kathleen A. Havlin, Vera Hárs, Wendy Demark‐Wahnefried, AH Partridge, Shari Gelber, R. Rosenberg, Clifford A. Hudis, C. Cirrincione, LA Carey and Larry Norton. Their work appears in journals such as Cancer Research, Annals of Oncology, Journal of Clinical Oncology and American Journal of Clinical Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sebastian LundgrenBreakdown of academic impact, for papers by C. SeynaeveBreakdown of academic impact, for papers by Lorenzo RossiBreakdown of academic impact, for papers by Friedrich OverkampBreakdown of academic impact, for papers by Valeria ForestieriBreakdown of academic impact, for papers by Domen RibnikarBreakdown of academic impact, for papers by Sara TaylorBreakdown of academic impact, for papers by Anne S. QuanteBreakdown of academic impact, for papers by C. I. LiBreakdown of academic impact, for papers by Lore Lapeire